Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114959 · ClinicalTrials.gov registry record · Phase 2
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
A Phase 2 study, sponsored by ChemGenex Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00114959 is a Phase 2 study that was terminated before completion, run by ChemGenex Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT00114959, a Phase 2 study, was terminated before completion, sponsored by ChemGenex Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This will be an open label, multi-center study of up to 77 patients with CML in chronic, accelerated or blast phase who have developed resistance to or have failed previous treatment with Gleevec (imatinib mesylate). Because these patients may still be sensitive to Gleevec, adding Homoharringtonine may restore a response to Gleevec or the combined treatment may promote a better response than using Gleevec alone.
Interventions
- DRUG Imatinib Mesylate
- DRUG Homoharringtonine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-10 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00114959
The ClinicalTrials.gov registry entry for NCT00114959 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ChemGenex Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imatinib Mesylate is the first listed.
NCT00114959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00114959 about?
NCT00114959 is a clinical study titled "Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)". This will be an open label, multi-center study of up to 77 patients with CML in chronic, accelerated or blast phase who have developed resistance to or have failed previous treatment with Gleevec (imatinib mesylate). Because these patients may still be sensitive to Gleevec, adding Homoharringtonine ...
What is the current status of trial NCT00114959?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2005-10. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00114959?
The interventions under investigation include: Imatinib Mesylate (DRUG), Homoharringtonine (DRUG).
Who is sponsoring clinical trial NCT00114959?
This trial is sponsored by ChemGenex Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.